A review on various aspect of COVID-19
This review is virtually focused on the current pandemic (Covid-19) , its pathogenesis and recent treatment available till date .As ,we know that covid-19, caused by SARS-COV 2 is highly mutating and transmissible virus which has put a new challange for development of vaccines and drugs to researchers worldwide. Among Corona virus, SARS-COV 2 is a 7th corona virus which is highly transmissible from human to human and no vaccines are available till date, due to this it has become a global threat for human being. It is believed to be zoonotic disease but no clean evidence of it main source has been known
Keywords: SARS-COV 2, Pandemic, Pneumonia, respiratory system.
2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020.
3. Liu Y, Gayle AA, Wilder-Smith A, Rocklov J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020.
4. Wuhan Municipal Health Commision. Wuhan Municipal Health and Health Commission’s Briefing on the Current Pneumonia Epidemic Situation in Our City. Available online http://wjw.wuhan.gov.cn/front/web/ show Detail/2019123108989
5. Zaki, A.M., et al., Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. New England Journal of Medicine, 2012; 367(19):1814-1820
6. Zhou, P., et al., Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. Biorxiv, 2020.
7 .Tang Q, Song Y, Shi M, Cheng Y, Zhang W, Xia XQ. Inferring the hosts of coronavirus using dual statistical models based on nucleotide composition. Sci Rep 2015; 5:17155
8. Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003; 302(5643):276-278
9. Drosten C, Kellam P, Memish Z A. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med. 2014; 371(14):1359-1360.
10. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020.
11. Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020; 9:386-9.
12. Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020; 382: 929-36.
13. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020.
14. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395: 507-13.
15. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020.
16. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367:1260-3.
17. Schwartz, D. A. (2020). An Analysis of 38 Pregnant Women with COVID-19, Their Newborn Infants, and Maternal-Fetal Transmission of SARS-CoV-2: Maternal Coronavirus Infections and Pregnancy Outcomes. Archives of Pathology & Laboratory Medicine. doi:10.5858/arpa.2020-0901-
18. Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020.
19. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395: 507-13
20. Wong, S. H., Lui, R. N., & Sung, J. J. Covid-19 and the Digestive System. Journal of Gastroenterology and Hepatology. 2020. doi:10.1111/jgh.15047
21. Cheng, H., Wang, Y., & Wang, G.Q. Organ-protective Effect of Angiotensin-converting Enzyme 2 and its Effect on the Prognosis of COVID-19.Journal of Medical Virology. 2020. doi:10.1002/jmv.25785
22. Huang, C., Wang, Y., Li, X., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet.doi:10.1016/s0140-6736 (20)30183-5
23. Imai Y, Kuba K, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005; 436: 112-116. DOI: 10.1038/nature03712
24. Huang C et. al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Published on 2020.Doi: org/10.1016/ S0140-6736(20)30251-8
25. Li, J.-Y., You, Z et. al. .The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Microbes and Infection: 2020. doi: 10.1016/j.micinf.2020. 02.002
26. Wang ML CR, Zhang L.k, Yang XL, Liu J, Xu MY, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020.
27. Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020; 35(6):e79.
28. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First Case of 2019 Novel Coronavirus in the United States. The New England journal of medicine. 2020.
29. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020 Feb doi:10.5582/bst.2020.01047
30. Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel corona virus pneumonia receiving combined Chinese and Western medicine treatment. Biosci trend.
31. Guo, Y.-R., Cao, Q.-D., Hong, Z.-S., Tan, Y.-Y., Chen, S.-D., Jin, H.-J., Yan, Y. (2020).The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Military Medical Research 7(1).doi:10.1186/s40779-020-00240-0
32. Zhang L, Liu Y. Potential Interventions for Novel Coronavirus in China: A Systematic Review. Journal of medical virology. 2020
33. Luo H, Tang QL, Shang YX, Liang SB, Yang M, Robinson N, et al. Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19) A Review of Historical Classics, Research Evidence and Current Prevention Programs. Chin J Integr Med. 2020.
34. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020
35. Guan W-j, Ni Z-y, Hu Y, Liang W-h, O u C-q, He J-x, et al. Clinical characteristics of 2019 novel corona virus infection in China.doi: 2020:2020.02.06.20020974
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).